Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia

Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio, commented: "DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GCGR, and GLP-1R. Developed using Doer Bio’s proprietary MultipleBody® platform technology, DR10624 was engineered to exhibit balanced activity for metabolic diseases. In non-clinical and clinical studies, DR10624 has demonstrated extraordinary potency in reducing lowering triglycerides, normalizing blood lipids, and improving liver function.”

Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio, added: “We're excited to announce the successful completion of patient enrollment in the DR10624-201 study. There is growing awareness of the public health threat posed by SHTG. Patients with SHTG face an increased risk of developing acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD), conditions that elevate the risk of hospitalization and death. The DR10624-201 study aims to determine the optimal dose for advancing DR10624 as a novel biologic treatment for patients suffering from SHTG. The topline data is expected in the third quarter of 2025”.